Anti-VEGF: Looking Forward in Lung Cancer
CME Monograph - July 2007
This educational monograph was developed for oncologists and other medical professionals who assess, counsel, and treat lung cancer patients. Program faculty are Thomas J. Lynch, Jr., MD Chief Oncology/ Hematology, MGH Cancer Center; Rebecca S Heist, MD, MPH, Department of Oncology, MGH Cancer Center, Tracey L Evans, MD, Department of Medicine, University of Pennsylvania School of Medicine, Mark A Socinski, MD, Program Director, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, Emer Hanrahan, MD, and Edward S Kim, MD, Department of Medicine, The University of Texas MD Anderson Cancer Center.
The educational objectives of the activity are to: discuss why vascular endothelial growth factor (VEGF) is considered to be an important target in lung cancer biology; assess current efficacy and safety data for bevacizumab, as well as issues and opportunities for its use in treating late-stage non-small cell lung (NSCLC) patients; and assess current efficacy and safety data for leading development-stage anti-VEGF agents in lung cancer treatment. The program was supported by educational grants from industry. Program management and CME sponsorship were provided by InforMEDical.
